LT3394065T - Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai - Google Patents

Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai

Info

Publication number
LT3394065T
LT3394065T LTEP15911490.9T LT15911490T LT3394065T LT 3394065 T LT3394065 T LT 3394065T LT 15911490 T LT15911490 T LT 15911490T LT 3394065 T LT3394065 T LT 3394065T
Authority
LT
Lithuania
Prior art keywords
tetrahydropyryanamin
pyrolopyrimidinone
Prior art date
Application number
LTEP15911490.9T
Other languages
English (en)
Inventor
Jean-Marc Lapierre
Sudharshan Eathiraj
Nivedita Namdev
Brian Schwartz
Yusuke Ota
Takayuki Momose
Tomoyuki Tsunemi
Hiroaki Inagaki
Kiyoshi Nakayama
Original Assignee
Arqule, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule, Inc. filed Critical Arqule, Inc.
Publication of LT3394065T publication Critical patent/LT3394065T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP15911490.9T 2015-12-23 2015-12-23 Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai LT3394065T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/000285 WO2017111787A1 (en) 2015-12-23 2015-12-23 Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof

Publications (1)

Publication Number Publication Date
LT3394065T true LT3394065T (lt) 2021-06-25

Family

ID=59090991

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP21165852.1T LT3882250T (lt) 2015-12-23 2015-12-23 Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
LTEP15911490.9T LT3394065T (lt) 2015-12-23 2015-12-23 Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP21165852.1T LT3882250T (lt) 2015-12-23 2015-12-23 Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui

Country Status (28)

Country Link
EP (2) EP3882250B1 (lt)
JP (1) JP6634520B2 (lt)
KR (2) KR102746900B1 (lt)
CN (2) CN108699062B (lt)
AU (3) AU2015417922B2 (lt)
CA (1) CA3008446C (lt)
CY (1) CY1124210T1 (lt)
DK (2) DK3882250T3 (lt)
ES (2) ES2942743T3 (lt)
FI (1) FI3882250T3 (lt)
HR (2) HRP20210844T1 (lt)
HU (2) HUE061761T2 (lt)
IL (2) IL259938B (lt)
LT (2) LT3882250T (lt)
MA (1) MA56553B1 (lt)
MD (1) MD3882250T2 (lt)
MX (1) MX384022B (lt)
MY (1) MY193177A (lt)
PH (1) PH12018501390B1 (lt)
PL (2) PL3882250T3 (lt)
PT (2) PT3394065T (lt)
RS (2) RS64141B1 (lt)
RU (1) RU2715421C2 (lt)
SA (1) SA518391836B1 (lt)
SG (1) SG11201805154YA (lt)
SI (2) SI3882250T1 (lt)
WO (1) WO2017111787A1 (lt)
ZA (1) ZA201804091B (lt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201901197PA (en) * 2016-08-24 2019-03-28 Arqule Inc Amino-pyrrolopyrimidinone compounds and methods of use thereof
CN109956870A (zh) * 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
BR112021023607A2 (pt) * 2019-05-31 2022-01-04 Fochon Pharmaceuticals Ltd Derivados de pirrolo[2,3-b]piridina e pirazolo[3,4-b]piridina substituídos por inibidores de proteína quinase
CN114728974B (zh) * 2019-11-13 2023-09-19 浙江龙传生物医药科技有限公司 作为btk抑制剂的吡咯并嘧啶类化合物及其应用
CN112812100B (zh) * 2019-11-18 2022-04-05 四川海思科制药有限公司 一种具有降解btk激酶的化合物及其制备方法和药学上的应用
CN112608318B (zh) * 2019-12-16 2023-09-08 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其用途
JP7011638B2 (ja) * 2019-12-16 2022-02-10 アークル インコーポレイテッド テトラヒドロピラニルアミノ-ピロロピリミジノンおよびその使用の方法
US20230122807A1 (en) * 2020-01-02 2023-04-20 Dizal (Jiangsu) Pharmaceutical Co., Ltd. Btk inhibitors
WO2022105746A1 (en) * 2020-11-17 2022-05-27 Fochon Pharmaceuticals, Ltd. SUBSTITUTED PYRROLO [2, 3-b] PYRIDINE AND PYRAZOLO [3, 4-b] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
CN112574200B (zh) * 2021-02-26 2021-06-11 安润医药科技(苏州)有限公司 Btk和/或btk的突变体c481s的小分子抑制剂
CN115028633B (zh) * 2021-03-08 2023-12-22 药雅科技(上海)有限公司 吡咯并嘧啶类化合物的制备及其应用
CN114761410B (zh) * 2021-04-06 2023-08-25 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
WO2022213932A1 (zh) * 2021-04-06 2022-10-13 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
JP7645573B2 (ja) * 2021-05-12 2025-03-14 ジャージアン・ロングチャーム・バイオ-テック・ファーマ・カンパニー・リミテッド ピロロピリミジン類化合物の結晶形およびその調製方法
US20250074911A1 (en) 2021-12-14 2025-03-06 Crossfire Oncology Holding B.V. Macrocyclic btk inhibitors
CN114409654A (zh) * 2021-12-30 2022-04-29 安徽普利药业有限公司 一种btk抑制剂的中间体合成方法
CN115894500B (zh) * 2022-11-02 2024-05-28 中国药科大学 一种作为btk激酶抑制剂的化合物及其制备方法与用途
CN118702697A (zh) * 2023-03-18 2024-09-27 山东新时代药业有限公司 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法
CN116375715B (zh) * 2023-04-06 2025-04-04 中国药科大学 一种作为非共价btk激酶抑制剂的化合物及其生物用途
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
KR20120097512A (ko) * 2009-11-18 2012-09-04 플렉시콘, 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US9012466B2 (en) * 2013-03-12 2015-04-21 Arqule Inc. Substituted tricyclic pyrazolo-pyrimidine compounds
US8940893B2 (en) * 2013-03-15 2015-01-27 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
GB201309085D0 (en) * 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
GB201410430D0 (en) * 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds

Also Published As

Publication number Publication date
CN113307811B (zh) 2023-11-14
LT3882250T (lt) 2023-05-25
HUE061761T2 (hu) 2023-08-28
ES2942743T3 (es) 2023-06-06
IL259938B (en) 2021-05-31
MA56553B1 (fr) 2023-04-28
PL3394065T3 (pl) 2021-08-02
IL259938A (en) 2018-07-31
CN113307811A (zh) 2021-08-27
PT3394065T (pt) 2021-05-06
MD3882250T2 (ro) 2023-06-30
WO2017111787A1 (en) 2017-06-29
AU2020203690B2 (en) 2021-08-05
HRP20210844T1 (hr) 2021-07-09
CY1124210T1 (el) 2022-05-27
KR20180096753A (ko) 2018-08-29
IL282572B (en) 2022-04-01
AU2015417922A1 (en) 2018-06-28
SI3394065T1 (sl) 2021-08-31
CA3008446C (en) 2023-10-10
SI3882250T1 (sl) 2023-07-31
MX2018007815A (es) 2019-07-04
BR112018012828A2 (pt) 2018-12-04
RS64141B1 (sr) 2023-05-31
JP2018538349A (ja) 2018-12-27
DK3394065T3 (da) 2021-05-31
EP3394065A4 (en) 2019-07-10
PL3882250T3 (pl) 2023-09-11
IL282572A (en) 2021-06-30
AU2019201737B2 (en) 2020-03-05
SA518391836B1 (ar) 2022-06-19
AU2020203690A1 (en) 2020-06-25
PH12018501390A1 (en) 2019-02-27
EP3882250B1 (en) 2023-02-15
RU2018126793A (ru) 2020-01-23
KR102746900B1 (ko) 2024-12-24
CA3008446A1 (en) 2017-06-29
HRP20230379T1 (hr) 2023-06-23
AU2019201737A1 (en) 2019-04-04
HUE055221T2 (hu) 2021-11-29
AU2015417922B2 (en) 2018-12-20
EP3394065B1 (en) 2021-04-07
MA56553A (fr) 2022-04-27
RU2018126793A3 (lt) 2020-01-23
RS61887B1 (sr) 2021-06-30
KR102547188B1 (ko) 2023-06-26
KR20230098690A (ko) 2023-07-04
ES2868884T3 (es) 2021-10-22
NZ743384A (en) 2024-05-31
EP3882250A1 (en) 2021-09-22
ZA201804091B (en) 2019-03-27
CN108699062A (zh) 2018-10-23
SG11201805154YA (en) 2018-07-30
EP3394065A1 (en) 2018-10-31
DK3882250T3 (da) 2023-05-22
FI3882250T3 (fi) 2023-04-27
PH12018501390B1 (en) 2022-06-10
CN108699062B (zh) 2021-06-29
MY193177A (en) 2022-09-26
RU2715421C2 (ru) 2020-02-28
PT3882250T (pt) 2023-04-21
MX384022B (es) 2025-03-14
JP6634520B2 (ja) 2020-01-22

Similar Documents

Publication Publication Date Title
FIC20230014I1 (fi) Foslevodopa ja foskarbidopa
LT3368534T (lt) Valbenazino ditozilatas ir jo polimorfai
LT3394065T (lt) Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai
LT3317284T (lt) Benzoksazepino oksazolidinono junginiai ir jų naudojimo būdai
LT3280441T (lt) Anti-sortilino antikūnai ir jų naudojimo būdai
LT3215532T (lt) Anti-tim3 antikūnai ir jų naudojimo būdai
LT3205650T (lt) Egfr inhibitorius ir jo gavimas bei taikymas
EP4135127C0 (en) MICRO-ASSEMBLY STRATEGIES AND DEVICES FOR COMPOUNDS
EP3205103C0 (en) INTER AND INTRA UNIFICATION BLOCK COPY
LT3333191T (lt) Anti-c10orf54 antikūnai ir jų panaudojimas
LT3412302T (lt) Modifikuoti fgf-21 polipeptidai ir jų panaudojimai
LT3099717T (lt) Antikūno molekulės tim-3-čiam ir jų panaudojimas
MA40933A (fr) Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
LT3319612T (lt) Oksisteroliai ir jų naudojimo būdai
EP3334572A4 (en) EXOANZUG
LT3102555T (lt) Junginių kompozicijos ir jų panaudojimas
DK3161139T3 (da) Tlr-4-specifikke aptamerer og anvendelser heraf
LT3303384T (lt) Neutralizuojančios surišančios molekulės prieš gripą ir jų naudojimas
LT3337506T (lt) Deriniai ir jų panaudojimas
LT3587420T (lt) Triciklis junginys ir jo naudojimas
PT3365321T (pt) Zwiterião de solabegron e suas utilizações
EP3324159A4 (en) PYRANOMETER
EP3340806A4 (en) STEVIA EXTRACTS
LT3247711T (lt) Naujos scy-078 druskos ir polimorfai
LT3309149T (lt) 6-brom-3-hidroksi-2-pirazinkarboksamido kristalas ir jo gamybos būdas